* Researchers at the Danish Headache Center are testing semaglutide along with a very low calorie diet as a treatment for new ...

Novo Nordisk named Maziar Mike Doustdar as its new chief executive on Tuesday, relying on an experienced company insider to ...

Novo Nordisk named Maziar Mike Doustdar as its new chief executive on Tuesday, relying on an experienced company insider to ...

In a surprise double announcement Tuesday, Novo reduced sales guidance by 5%—attributing the change to slowed growth of its ...

Novo Nordisk named Maziar Mike Doustdar as its new chief executive today, relying on an experienced company insider to revive sales and a share price hit by worries the maker of weight-loss drug ...

Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its ...

COPENHAGEN (Reuters) -Investors knocked $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss ...

Since the US Food and Drug Administration (FDA) implemented a ban on ‘compounded’ versions of Wegovy on 22 May, new ...

The announcement came amid a slump in the company's share price and investor concerns about its experimental drug pipeline ...

Danish pharma giant Novo Nordisk named Maziar Mike Doustdar as its new chief executive on Tuesday, relying on an experienced company insider to ...

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

Novo Nordisk A/S lowered its financial forecast in a surprise update that cited lagging sales of its weight-loss drug Wegovy, ...